Globus Medical (GMED) EBITDA (2011 - 2026)

Globus Medical has reported EBITDA for 16 years, with the latest figure at $123.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 53.9% year-over-year to $123.4 million; the trailing twelve-month figure through Mar 2026 stood at $603.3 million (up 210.26% YoY), and the FY2025 full-year result was $560.1 million, up 426.81% from the prior year.
• EBITDA for Q1 2026 stood at $123.4 million, down from $145.0 million in the prior quarter.
• The five-year high for EBITDA was $215.3 million in Q2 2025, with the low at -$8.0 million in Q1 2024.
• Historically, EBITDA has averaged $64.7 million across 5 years, with a median of $54.3 million in 2023.
• The largest YoY upside for EBITDA was 4168.17% in 2024 against a maximum downside of 114.67% in 2024.
• Globus Medical's EBITDA stood at $57.7 million in 2022, then sank by 59.11% to $23.6 million in 2023, then climbed by 12.85% to $26.6 million in 2024, then surged by 445.02% to $145.0 million in 2025, then fell by 14.93% to $123.4 million in 2026.
• The last three EBITDA figures came in at $123.4 million (Q1 2026), $145.0 million (Q4 2025), and $119.7 million (Q3 2025), per Business Quant data.